Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136798 · ClinicalTrials.gov registry record · NA
Impact of Exenatide on Sleep in Type 2 Diabetes
A NA study of Type 2 Diabetes and Sleep Disordered Breathing, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT01136798: Completed NA study of Type 2 Diabetes and Sleep Disordered Breathing, sponsored by University of Chicago.
NCT01136798 is a NA study of Type 2 Diabetes and Sleep Disordered Breathing that has completed, run by University of Chicago. The registered enrollment target is 18 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01136798, a NA study of Type 2 Diabetes and Sleep Disordered Breathing, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in sleep and measures of metabolic and circadian function. This project would be the first to probe the relationship between incretin hormone regulation, duration and intensity of sleep, glucose tolerance and circadian dysfunction in diabetic patients.
Primary Outcome
Total minutes of non-REM sleep was measured
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Exenatide
Study Locations (2)
Illinois
- The University of Chicago - Chicago
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-06-01 |
| Est. Completion | 2016-09-01 |
| Phase | NA |
What the finished NCT01136798 record still lists
NCT01136798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01136798 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT01136798 about?
NCT01136798 is a clinical study titled "Impact of Exenatide on Sleep in Type 2 Diabetes". The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relationship between improvements in sleep and measures of metabolic and circadian function. This project w...
What is the current status of trial NCT01136798?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2010-06-01. Estimated completion is 2016-09-01.
What conditions does trial NCT01136798 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Sleep Disordered Breathing.
What interventions are being tested in trial NCT01136798?
The interventions under investigation include: Placebo (DRUG), Exenatide (DRUG).
Who is sponsoring clinical trial NCT01136798?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01136798 being conducted?
This trial has 2 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01136798's enrollment target sits among peer trials
18 306th of 327 higher than 22 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI